In Brief: J&J/Merck
This article was originally published in The Tan Sheet
Executive Summary
J&J/Merck: Joint venture records sales of $530.2 mil. in 1996 in the U.S., Europe and Canada -- an increase of $126.7 mil. over 1995 sales. The joint venture's major products are Pepcid AC, the leading product in the H2 antagonist category, and Mylanta. J&J/Merck recently expanded its gastrointestinal line with the introduction of Mylanta AR, a formulation identical to Pepcid AC, in late January ("The Tan Sheet" Jan. 13, p. 3)...
J&J/Merck: Joint venture records sales of $530.2 mil. in 1996 in the U.S., Europe and Canada -- an increase of $126.7 mil. over 1995 sales. The joint venture's major products are Pepcid AC, the leading product in the H2 antagonist category, and Mylanta. J&J/Merck recently expanded its gastrointestinal line with the introduction of Mylanta AR, a formulation identical to Pepcid AC, in late January ("The Tan Sheet" Jan. 13, p. 3).... |